Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
The Guthrie Clinic, Sayre, Pennsylvania, USA.
Curr Opin Urol. 2019 Sep;29(5):548-555. doi: 10.1097/MOU.0000000000000618.
Renal transplant is needed for end-stage renal disease. Although treatment of donor stones may be needed pretransplant and increases the pool available for renal transplant, posttransplant stone disease may also need treatment to maintain the allograft function. A Cochrane style review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to evaluate the outcomes of donor and posttransplant ureteroscopy (URS) for stone disease, including all English language articles between January 1996 and December 2018.
Eighteen articles (167 patients), seven ex-vivo or donor URS and 11 posttransplant URS met inclusion criteria and were included in the review. A pretransplant URS showed a stone-free rate (SFR) of 100% with an overall complication rate of 7.5% (four Clavien I and one Clavien ≥3), where as a posttransplant URS showed SFR of 100% in five studies and 60-91% in four studies with an overall complication rate of 12.9% (10 Clavien I and three Clavien ≥3).
Advancements in endourological technique has made URS for donor and posttransplant urolithiasis a safe and effective procedure. Although data were based on small retrospective caser series, it shows that in experienced centres it can be performed with low morbidity and a high SFR.
终末期肾病需要进行肾移植。虽然移植前可能需要治疗供体结石,并增加可用于肾移植的供体数量,但移植后结石病也可能需要治疗以维持移植物功能。我们按照《系统评价和荟萃分析的首选报告项目》指南进行了一项 Cochrane 式综述,以评估供体和移植后输尿管镜检查(URS)治疗结石病的结果,包括 1996 年 1 月至 2018 年 12 月期间所有英文文章。
18 篇文章(167 例患者),包括 7 篇离体或供体 URS 和 11 篇移植后 URS,符合纳入标准并纳入综述。一项移植前 URS 的无石率(SFR)为 100%,总体并发症发生率为 7.5%(4 例 Clavien I 和 1 例 Clavien≥3),而移植后 URS 的 SFR 在 5 项研究中为 100%,在 4 项研究中为 60-91%,总体并发症发生率为 12.9%(10 例 Clavien I 和 3 例 Clavien≥3)。
腔内泌尿外科技术的进步使供体和移植后尿石症的 URS 成为一种安全有效的治疗方法。尽管数据基于小型回顾性病例系列,但表明在经验丰富的中心,它可以以低发病率和高 SFR 进行。